Adaptive Biotechnologies (ADPT) Soars 12.03% on Expanded Medicare Coverage

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) saw a significant pre-market rise of 12.03% on April 8, 2025, driven by positive news regarding its clonoSEQ® test.

Adaptive Biotechnologies announced that Palmetto GBA, a Medicare Administrative Contractor, has expanded coverage of clonoSEQ® to include single time point testing for monitoring recurrence in patients with a history of mantle cell lymphoma (MCL). This expansion allows patients who have completed treatment to receive clonoSEQ testing every six months for up to five years during treatment-free remission and annual testing thereafter until disease recurrence is detected.

This decision underscores the clinical utility of clonoSEQ testing and establishes a framework for potential expanded coverage of surveillance testing in other Medicare-covered clonoSEQ indications. MCL is a subtype of non-Hodgkin lymphoma with an annual incidence of approximately 4,000 cases per year in the United States. Ongoing recurrence monitoring is particularly important in MCL, and clonoSEQ MRD testing in blood provides longitudinal insights that can be used to limit or guide imaging in this setting.

clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at Adaptive's CLIA-certified lab in Seattle. The test leverages Adaptive Biotechnologies’ proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment.